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Numerous analyses of large patient cohorts identified specific patterns of immune activation associated with
patient survival. We established these as the immune contexture, encompassing the type, functional orien-
tation, density, and location of adaptive immune cells within distinct tumor regions. Based on the immune
contexture, a standardized, powerful immune stratification system, the Immunoscore, was delineated. The
immune contexture is characterized by immune signatures also observed in association with the broader
phenomenon of immune-mediated, tissue-specific destruction. We defined these as the immunologic
constant of rejection. Predictive, prognostic, and mechanistic immune signatures overlap, and a continuum
of intratumor immune reactions exists. The balance between tumor cell growth and elimination may be
tipped upon a crescendo induced by immune manipulations aimed at enhancing naturally occurring immu-
nosurveillance. Here, we propose a broader immunological interpretation of these three concepts—immune
contexture, Immunoscore, and immunologic constant of rejection—that segregates oncogenic processes
independently of their tissue origin.Introduction
High-throughput technology has provided an unbiased global
view of biological processes. This strategy, applied to the
analysis of tumor tissue, defined immune characteristics that
are associated with the natural or treatment-induced evolution
of cancer. Although epidemiological and observational studies
in humans have shown that chronic inflammation promotes
tumorigenesis (Trinchieri, 2012), when patients bearing estab-
lished tumors are prospectively followed, the role of a polarized
immunity process counteracting tumor growth and progression
emerges.
Observational studies linked to clinical-outcome analysis
suggest the existence and relevance in humans of the immuno-
surveillance phenomenon, characterized earlier by Schreiber
and colleagues through elegant studies in animals (Shankaran
et al., 2001). According to the immunoediting theory, the host
can control tumor growth through the activation of adaptive
and innate immune mechanisms, driven by the activation of
interferon-g (IFN-g)-dependent pathways (Schreiber et al.,
2011). This process can also lead to the selection of tumor cells
capable of escaping the immune pressure, which explains the
paradoxical observation of tumor development in immune-
competent individuals (Schreiber et al., 2011). However, a
convincing number of observations have demonstrated that
the presence and maintenance of an inflammatory status in or
by established tumors is associated with a more favorable prog-
nosis and/or treatment responsiveness.
Redundant signatures are observed among cancers with a
better prognostic connotation (prognostic signatures), cancers
with an increased likelihood to respond to therapy (predictivesignatures), or cancers studied during treatments that sub-
sequently underwent complete regression (mechanistic sig-
natures). Moreover, similar pathways are shared by other
phenomena in which tissue-specific immune destruction occurs,
such as autoimmune diseases, allograft rejection, graft-versus-
host disease (GVHD), and acute infection resulting in clearance
of pathogen-infected cells.
Here, we will focus on dominant themes shared by the
aforementioned conditions related to positive outcomes in
cancer, whereas other salient characteristics of the tumor
microenvironment that may otherwise affect the behaviors of
tumors predominantly toward negative outcomes are not
included in this review (e.g., see Motz and Coukos, 2013 in this
issue). Three concepts will be defined, compared, and dis-
cussed here: the immune contexture, the Immunoscore, and
the immunologic constant of rejection (ICR) (Figures 1 and 2).
Historical Perspective
Contrary to those who view the field as nothingmore thanwishful
thinking, cancer immunology has made many major discoveries
and established a strong foundation over the last century. From
its origins, the field has been plagued by difficulties. Firstly, can-
cer immunology is a hybrid discipline. Secondly, the cancer field
was previously led predominantly by geneticists, oncologists,
pathologists, and other medical specialists. However, as early
as the 1890s, William B. Coley observed that some cancer
patients experienced spontaneous remission of their tumors
when they contracted acute infections (Coley, 1893). Coley
went on to develop a relatively safe and effective mixture of bac-
terial products (Coley’s toxins) for treating cancer patients. ThisImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 11
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Figure 1. Graphical Representation of the
Immune Contexture, the Immunoscore,
and the ICR
The immune contexture is defined as the type,
functional orientation, density, and location of
adaptive immune cells within distinct tumor re-
gions. The parameters establishing the immune
contexture are comprised of the density of CD3+,
CD8+, and CD45RO+ T cells and their location at
the tumor center and invasive margin combined
with the quality of tertiary LIs. Numerous analyses
of large patient cohorts confirmed an association
between these patterns and favorable disease
outcome. The Immunoscore is derived from three
aspects of the immune contexture: the type,
density, and location of immune cells. The func-
tional orientation of the immune contexture is
characterized by immune signatures qualitatively
similar to those predicting response to immuno-
therapy, which are observable in association with
the broader phenomenon of immune-mediated,
tissue-specific destruction. These signatures are detectable during regression of cancer following immunotherapy, allograft rejection, GVHD, flares of auto-
immunity, or destruction of virally infected cells to clear intracellular pathogens. We defined them as the immunologic constant of rejection (ICR). Genes
underlying Th1 polarization, related chemokines (CXCR3 and CCR5 ligands), and genes associated with the activation of cytotoxic mechanisms more frequently
described in association with the broader phenomenon of immune-mediated, tissue-specific destruction (ICR genes) are in bold.
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Reviewwork was overshadowed, however, by the advent of X-ray and
radium treatment and, subsequently, chemotherapy. The field
of immunology during these first visionary years remained ne-
glected. During the mid-20th century, Richmond Prehn and
Joan Main demonstrated immune rejection of transplanted syn-
geneic chemically-induced tumors (Prehn and Main, 1957). A
few years later, based on increasing observations in mouse
models, Lewis Thomas andMcFarlane Burnet proposed a theory
of ‘‘immune surveillance of cancer,’’ speculating that the immune
system might be capable of destroying nascent malignancies
(Burnet, 1970; Thomas, 1982). The concept of cancer immune
surveillance becamemoribund following the finding that athymic
nude mice did not have increased susceptibility to tumors
induced by methylcholanthrene (Stutman, 1974, 1975). Howev-
er, we now know that nude mice have high levels of natural killer
(NK) cells and other innate immune cells (Dunn et al., 2004).
Regardless of these major discoveries, the cancer immu-
nology field became increasingly controversial, and the scientific
validity of Coley’s diagnosis was questioned. This pessimistic
view of cancer immunity was gradually rebutted by many novel
experimental observations, such as the discovery of the tumor
necrosis factor (Carswell et al., 1975) and the demonstration of
the rejection of poorly immunogenic spontaneous tumors after
immunization with mutagenized tumors (Van Pel et al., 1983).
In 1991, the field entered the molecular era of immunology with
the identification of antigen structures and the sequences of
genes encoding tumor antigens that are recognized by T cells
(van der Bruggen et al., 1991). This discovery generated a
wave of optimism and hope for vaccination and immune-modu-
latory approaches against cancer. In 1995 and 1998, two inflam-
matory cytokines, IFN-a and interleukin-2 (IL-2), were approved
for the treatment of melanoma (adjuvant andmetastatic settings,
respectively). However, immonotherapies developed in these
years had limited survival benefit restricted to a minor group of
patients, again plunging the field into question.
The renaissance of tumor immunology really began a decade
ago, spurred by three major achievements. First, there was the
demonstration of immunosurveillance (integrated in the immu-12 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.noediting theory) using gene-deletionmousemodels (Shankaran
et al., 2001) and the demonstration of the equilibrium phase of
cancer (Koebel et al., 2007). Second, there was the demonstra-
tion of the importance of the patients’ tumor immune reaction
for their survival. Adaptive immune cell infiltration was shown
to have a prognostic value superior to the classical extension
and invasion tumor criteria (Galon et al., 2006, 2007). Moreover,
an active-tumor microenvironment conducive to immune recog-
nition was shown to be predictive of response to immunotherapy
(Wang et al., 2002). Third, the remarkable successes of several
immunotherapies generated tremendous enthusiasm among
oncologists and immunologists. In the last five years, several
types of immunotherapies have been shown to have great clin-
ical impact. These include adoptive T cell transfer therapy (Kalos
and June, 2013; Restifo et al., 2012); vaccines such as the first
cellular vaccine approved by the United States Food and Drug
Administration (FDA), Sipuleucel-T (Kantoff et al., 2010); and
the gp100 vaccine in combination with IL-2 (Schwartzentruber
et al., 2011). Additionally, checkpoint blockade inhibitors, such
as the FDA-approved anti-CTLA4 monoclonal antibody (mAb)
(ipilimumab) (Hodi et al., 2010; Robert et al., 2011) and the
anti-PD-1:PD-1 ligand mAbs (Brahmer et al., 2012; Topalian
et al., 2012), have recently revolutionized the field (Chen and
Mellman, 2013). The area of cancer immunology remains an
ever-increasing multidisciplinary field, thriving from the input of
immunologists and clinicians alike who work in concert to save
the lives of cancer patients.
Prognostic Immune Signatures in Distinct Types of
Cancer
Prognostic markers are clinical measures used to evaluate indi-
vidual patient outcome, such as recurrence of disease or death,
independent of therapy. These prognostic factors range from
simple measures, such as the stage of disease based on tumor
invasion, to progressively more comprehensive indicators
encompassing the biological complexity of the disease (Bindea
et al., 2010; Galon et al., 2007). Indeed, the evolution of cancer
is greatly influenced by the complex milieu in which it develops,
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Figure 2. Overlap between the Immune
Contexture, the Immunoscore, and the ICR
The top panel is a diagrammatic representation
of the immune contexture defined in cancer and
its overlap with the Immunoscore and with the
ICR seen in other diseases. The bottom panel
highlights the characteristics of these three
concepts. The immune contexture represents
the complexity of the immune parameters within
the tumor microenvironment associated with
patient survival; the Immunoscore represents a
standardized, simple, and powerful immune
stratification system, proposed as a novel method
for routine testing; and the ICR represents the
immune gene signatures observed in association
with tissue-specific destruction.
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Reviewaccommodating intricate tumor-cell interactions within the
host microenvironment including a vast catalog of cells, vessels,
cytokines, and chemokines. Histological analysis of human
tumors has highlighted the importance of tumor immune
infiltrates including macrophages, dendritic cells (DCs), poly-
morphonucleate cells, NK cells, B cells, and T cells, revealing
a broad patient-to-patient diversity (Mlecnik et al., 2011a; Seno-
villa et al., 2012). Among an increasing variety of investigations
supporting the relevance of the differential presence of com-
ponents of the immune system in determining the evolution of
cancer (Jochems and Schlom, 2011), a predominant theme
based collectively on direct human observations suggests that
high densities of tumor-infiltrating lymphocytes correlate with
improved clinical outcome (Mlecnik et al., 2011a). The correla-
tion between a robust lymphocyte infiltration and patient survival
has been well documented in melanoma, ovarian, head and
neck, breast, urothelial, colorectal, lung, hepatocellular, gall-
bladder, and esophageal cancer (reviewed in Angell and Galon,
2013; Fridman et al., 2012). Themajority of studies observed that
high densities of CD3+ T cells, CD8+ cytotoxic T lymphocytes
(CTLs), and CD45RO+ memory T cells are associated with a
longer disease-free survival (DFS) and/or improved overall sur-
vival (OS). Thus, the role of the adaptive immune response
in controlling tumor progression is becoming increasingly
appreciated. These prognostic immune parameters have been
comprehensively described in colorectal cancer (CRC) as the
immune contexture, which is defined as the type, density, func-
tional orientation, and location of adaptive immune cells within
distinct tumor regions (Fridman et al., 2012; Galon et al., 2006,
2007). The parameters establishing the immune contexture
consist of the density of CD3+, CD8+, and CD45RO+ T cells
and their location at the tumor center (CT) and invasive margin
(IM), combined with the quality of tertiary lymphoid islets (LIs).
These morphological parameters are consistently associated
with a functional connotation reflecting activation of T helper
type 1 (Th1) cell-related factors such as IFN-g (IFNG), signal
transducers and activator of transcription 1 (STAT1), IL-12
(IL12), IFN-regulatory factor 1 (IRF1), the transcription factorImmunitT-bet (TBX21), immune effector or cyto-
toxic factors (granzymes [GZMs], perforin
[PRF1], and granulysin [GNLY]), CXCR3
and CCR5 ligand chemokines (CXCL9,
CXCL10, and CCL5), other chemokines(CX3CL1 and CCL2), and adhesion molecules (MADCAM1,
ICAM1, and VCAM1) (Figure 1). Chemoattraction and adhesion
were shown to play critical roles in determining the density of in-
tratumoral immune cells. Expression of these specific chemo-
kine signatures correlated with differing densities and spatial
localization of T cell subpopulations within tumor regions and
with specific T cell receptor (TCR) repertoires, predicting patient
survival (Mlecnik et al., 2010). High expression levels of these im-
mune-related genes were associated with prolonged DFS in pa-
tients with CRC, and long-termOS correlated with these immune
gene signatures (Mlecnik et al., 2010).
Gene signatures characterized by the activation of immune-
related genes such as chemokines (CXCL9 and CXCL10),
cytotoxic granules (GZMA and GZMB), T cell markers (CD8A),
human leukocyte antigen (HLA) molecules and other IFN-stim-
ulated genes (STAT1 and GBP1) (Ascierto et al., 2012), and
NK-related genes (Ascierto et al., 2013) were observed in tu-
mors from patients with early-stage breast cancer who enjoyed
prolonged DFS. Interestingly, and in line with this observation,
analysis of a large cohort of breast cancer samples identified
a specific cluster of good-prognosis tumors characterized by
a low number of somatic copy-number aberrations and by
the upregulation of congruent immune genes (e.g., CD3D,
CD8A, CCL5, CXCL9, CXCL10, CXCR3, STAT1, and other
IFN-stimulated genes) (Curtis et al., 2012). Similar associations
were also observed in additional colorectal, lung, hepa-
tocellular, ovarian, melanoma, and breast cancer studies
(Ascierto et al., 2012; Chew et al., 2012; Curtis et al., 2012; Des-
medt et al., 2008; Galon et al., 2006; Jiang et al., 2010; Leffers
et al., 2010; Mann et al., 2013; Messina et al., 2012;
Mlecnik et al., 2010; Moran et al., 2002; Page`s et al., 2005; To-
solini et al., 2011; Verhaak et al., 2013; Zhang et al., 2003) (Ta-
ble 1). Table 1 summarizes gene-signature data, but does not
include additional valuable research from other approaches,
such as flow cytometry and immunohistochemistry. Notably,
as discussed later, a large proportion of the activation sig-
natures associated with good prognosis are observed in other
conditions related to immune-mediated, tissue-specificy 39, July 25, 2013 ª2013 Elsevier Inc. 13
Table 1. A Summary of the Key Studies and Overlapping Genetic Pathways Observed in Prognostic, Predictive, and Mechanistic
Signatures
Cancers
Th1 Chemokines Cytotoxic Adhesion
References
STAT1 IRF1/
IFN-g-SG
Pathway
CXCR3/
CXCL9–11
Pathway
CCR5/
CCL3–5
Pathway
Granzyme Perforin
Granulysin/TIA1/
Caspase Pathway
Adhesion
Molecules
Prognostic
Breast + + + + Ascierto et al., 2012
+ + + + Curtis et al., 2012
+ Desmedt et al., 2008
Ovarian + + + + Leffers et al., 2010
+ + Zhang et al., 2003
+ Verhaak et al., 2013
Melanoma + + Messina et al., 2012
+ + + + + Mann et al., 2013
Colorectal + + + + + Mlecnik et al., 2010
+ + Galon et al., 2006
+ + Page`s et al., 2005
+ + + Tosolini et al., 2011
+ Jiang et al., 2010
Lung + Moran et al., 2002
Hepatocellular + + + + Chew et al., 2012
Predictive
Breast (chemo) + Denkert et al., 2010
+ Ignatiadis et al., 2012
Melanoma (IL-2/
vaccine/ adoptive
therapy/anti-CTLA4)
+ + Wang et al., 2002
+ Weiss et al., 2011
+ + Gajewski et al., 2007, ASCO, abstract
+ + Bedognetti et al., 2012,
ASCO, abstract
+ + + + + Ji et al., 2012
+ + + + Ulloa-Montoya et al., 2013
Lung (vaccine) + + + + Ulloa-Montoya et al., 2013
Mechanistics
Melanoma (IL-2/
vaccine/anti-CTLA4)
+ + + + + Panelli et al., 2002
+ Wang et al., 2002
+ + Weiss et al., 2011
+ + + Carretero et al., 2012
+ + + + + Ji et al., 2012
Basal cell carcinoma
(imiquimod)
+ + + + Panelli et al., 2007
The abbreviations used are as follows: Th1, T helper cell type 1; STAT, signal transducers and activator of transcription; IFN-g-SG, interferon-g-stim-
ulated genes; IRF, IFN-regulatory factor; chemo, chemotherapy; IL-2, interleukin-2.
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Reviewdestruction and are therefore included in the concept of
the ICR.
Traditionally, tumor-invasion parameters such as the
anatomic extent of the tumor burden (T), the presence of cancer
cells in draining lymph nodes (N), and evidence of distant metas-
tases (M) have been combined to provide the American Joint
Committee on Cancer/Union Internationale Contre le Cancer
(AJCC/UICC) TNM classification, serving as the prominent
prognostic stratification system. This classification has proved
valuable in estimating the outcome of patients for a variety of14 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.cancers (Wittekind et al., 2002). However, it is recognized that
clinical outcome can vary significantly among patients within
the same histological stage (Nagtegaal et al., 2012). Data
collected from large cohorts of human CRCs have demonstrated
the impact of an immune-based classification strategy, utilizing
a simple test derived from the immune contexture that has
been termed the Immunoscore (Figures 1 and 2). The Immuno-
score (I) is based on the densities of two lymphocyte populations
(CD3+, CD8+, or CD45RO+ cells) quantified within the CT and
IM. These parameters provide a scoring system ranging
Immunity
Reviewincrementally from Immunoscore 0 (I0), which has low densities
of both cell types in both regions, to Immunoscore 4 (I4), which
has high densities of both cell populations in both regions. The
prognostic value of using these criteria was demonstrated in
patients with early-stage CRC (TNM stages I and II) for predicting
survival and relapse (Page`s et al., 2009), wherein the five Immu-
noscore groups were associated with highly significant changes
in DFS and OS (p < 0.0001). Patients with I4 survived for a long
time; 95% of the I4 patients had no tumor recurrence for 18
years, whereas 50% of I0 patients had tumor recurrence within
2 years. The prognostic value was then demonstrated in patients
at all cancer stages (TNM stages I–IV) (Mlecnik et al., 2011b).
More importantly, for the first time, combined evidence illus-
trates the dependency of TNM staging stratification on factors
of the immune response (Galon et al., 2006; Mlecnik et al.,
2011b). Indeed, Cox multivariate analysis shows that tumor
progression (T stage) and invasion (N stage) are statistically
dependent on the Immunoscore. The Immunoscore remained
the only significant criterion over TNM staging for DFS or OS,
illustrating that it may have a prognostic value superior to the
TNM classification (Broussard and Disis, 2011; Galon et al.,
2006; Mlecnik et al., 2011b). Thus, lymphocyte infiltration asso-
ciated with a Th1 cell polarization of the adaptive immune
response bears a significant impact on the natural history of can-
cer patients.
Predictive Immune Signatures in Distinct Types
of Cancer
Prognosticmarkers are useful for assessing the risk of an individ-
ual patient and providing helpful insights into cancer biology.
However, they do not assist in treatment selection according
to the likelihood of therapeutic effectiveness, a role that pertains
to predictive biomarkers (Angell and Galon, 2013). Numerous
therapeutic regimes are currently used to treat cancer, including
radiotherapy, chemotherapy, kinase inhibitors (e.g., BRAF and
c-Kit inhibitors; Corless et al., 2011; Sharma et al., 2012), and
antibody therapy directed to proteins expressed by cancer cells
(e.g., HER2, EGFR, andCD20; Galluzzi et al., 2012c) or to soluble
factors favoring tumor growth through the perturbation of the tu-
mor microenvironment (i.e., vascular endothelial growth factor;
Terme et al., 2013).
In addition to the immunotherapies mentioned earlier, other
immunotherapeutic approaches such as Toll-like receptor
(TLR) agonist (Vacchelli et al., 2012a; van den Boorn and Hart-
mann, 2013), novel generation of DC-based vaccination (Pal-
ucka and Banchereau, 2013; Galluzzi et al., 2012a; Vacchelli
et al., 2012c), and engineered T cell transfer therapy (Kalos
and June, 2013; Restifo et al., 2012) have been shown to induce
significant antitumor activity. In most cases, responses were
largely unpredictable and restricted to a limited portion of pa-
tients. Several in vitro and in vivo experiments, as well as a few
clinical observations, suggest that not only immunotherapeutic
approaches, but the majority of the aforementioned therapies
(Frederick et al., 2013; Fridman et al., 2012; Galluzzi et al.,
2012b; Ma et al., 2013) including radiotherapy (Formenti and De-
maria, 2013) can trigger an immune-mediated antitumor
response (Figure 3A). Among the hurdles related to the develop-
ment of novel anticancer immunotherapies stands the absence
of biomarkers predictive of immune responsiveness. Recentstudies have begun to highlight the role that tumor cell death trig-
gered by chemotherapy may play as an immune adjuvant
contributing to treatment success (Vacchelli et al., 2012b; Zitvo-
gel et al., 2013, this issue). Pari passu, investigations aimed at
assessing the presence of a strong immune infiltrate and its func-
tional or molecular orientation supported its role in predicting
therapeutic response (Fridman et al., 2012).
High-throughput gene-expression profiling unveiled dominant
themes that are consistently linked to the effectiveness of
distinct approaches (Bedognetti et al., 2010). Notably, molecular
pathways predictive of immune responsiveness largely overlap
with those associated with favorable prognosis. A decade ago,
gene-expression profile studies first suggested that metastatic
melanoma lesions likely to respond to IL-2 and vaccination
bear an inflammatory status characterized by the preactiva-
tion of cytotoxic mechanisms and the upregulation of IFN
signaling (Wang et al., 2002). Moreover, real-time quantitative
PCR (qPCR) measurement demonstrated similar expression of
lymphoid cell markers (e.g., CD3D and CD8A) in pretreatment
responding versus nonresponding lesions. This observation
suggests that some tumors might display a functional active
immunophenotype independently of the abundance of infil-
trating immune cells (Wang et al., 2002). Furthermore, gene
signatures including T cell markers and specific chemokines
were associated with favorable prognosis in two metastatic-
melanoma trials, evaluating the activity of multiple peptide vacci-
nation plus IL-12 and DC-based vaccination (Gajewski et al.,
2010; Gajewski et al., 2007, ASCO, abstract; Gajewski et al.,
2009, ASCO, abstract). More refined network and pathway ana-
lyses recently confirmed and better defined these early findings.
In a prospective pilot study, Weiss et al. (2011) showed that pre-
treatment biopsies of lesions from patients with metastatic mel-
anoma subsequently responding to the administration of IL-2
displayed a signature of immune activation, centered on IFN-g
signaling. Ji et al. (2012) recently applied gene-expression
profiling to the study of melanoma metastases from patients
treated with anti-CTLA4 (ipilimumab). The top 26 genes upregu-
lated in samples from responding patients include CD8A, HLA-
DQA1, CCL4, and CCL5 (CCR5 ligands); CXCL9, CXCL10, and
CXCL11 (CXCR3 ligands); and NKG7, GZMB, and PRF1 (im-
mune effectors). In line with these findings, a coordinated upre-
gulation ofCCL5,CXCL9,CXCL10, andCXCL11 in pretreatment
lesions was found to be predictive of responsiveness to adop-
tive-transfer therapy and IL-2 in the same disease setting (Bed-
ognetti et al., 2012, ASCO, abstract).
Notably, in the aforementioned ipilimumab trial (Ji et al., 2012),
the overexpression of IDO1 (a classical immunosuppressive
gene) also correlates with treatment effectiveness. Concor-
dantly, in the same setting, the pretreatment overexpression of
FOXP3 (a marker of bona-fide T regulatory cells) and IDO pro-
teins by immune infiltrates positively correlates with ipilimumab
efficacy (Hamid et al., 2011). Similarly, only tumors expressing
PD-1 ligands seem to be sensitive to anti-PD1 therapy (Topalian
et al., 2012). Overall, the studies evaluating immune-checkpoint
blockade molecules (i.e., anti-CTLA4 and anti-PD1/anti-PD1
ligand mAbs) have provided two important hypotheses. The first
is that, in metastatic cancers, the immune system is not an inert
system, but rather an actively suppressed one. The second
hypothesis is that tumors responsive to treatment displayImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 15
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Figure 3. The Molecular Continuum between Prognostic, Predictive, and Mechanistic Signatures
(A) Postulated impact of cancer treatments on the tumor microenvironment. Therapies designed to target tumor cells can also induce changes in the immune
response and tumor microenvironment. These responses are amplified in the setting of immunotherapies, which boost naturally occurring (but suppressed)
antitumor immune response. In some patients this intratumoral immune response can slow down tumor growth or eventually mediate long-lasting tumor
regression. Chemo, chemotherapy; Radio, radiotherapy; Small molec, small molecules (kinase inhibitors); Tumor-mAbs, tumor-directed antibodies; Immune-
mAbs, immune-directed antibodies (checkpoint blockade inhibitors); TLR, toll-like receptor agonists; CYT, cytokines (i.e., IL-2); VAC, vaccines; ACT, adoptive
cell-transfer therapy.
(B) Proposed quantitative continuum between prognostic, predictive and mechanistic signatures. It could be hypothesized that the lowest level of immune
activation is a feature of predictive signatures that cannot affect tumor growth (or risk of recurrence when the primary tumor is excised) in natural conditions. It is
followed by prognostic signatures of insufficient intensity to cause cancer eradication but capable of controlling tumor growth (or tumor recurrence). Themaximal
intensity of immune response (captured by mechanistic signatures) occurs in lesions that are about to regress after immunotherapy administration.
(C) Potential qualitative difference in overlap between immune and nonimmune prognostic, predictive, and mechanistic signatures. Only immune signatures
measure the status of activation of a naturally protectivemechanism, which, if successfully elicited, can lead to tumor regression. For this reason it is probable that
predictive immune signatures will overlap (qualitatively) with the prognostic and the mechanistic ones. This is not the case, however, of nonimmune-related
signatures, which, in general, measure cancer cell centric characteristics.
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Reviewan inflammatory status accompanied by the concomitant coun-
teractivation of immune-suppressive mechanisms, probably re-
flecting ongoing immune-escape processes. This suppressed
immune response could however be restored by the blockade
of the immune checkpoint. Tumors lacking these two character-
istics are insensitive to therapeutic immune manipulations. It is
not known whether this deficiency depends on the intrinsic
inability of some tumors to trigger the immune system ab initio
or whether it is the result of an immunologic epilog in which im-
mune-escape mechanisms have conclusively prevailed.
Robust data from two randomized phase II trials recently iden-
tified a signature predictive of responsiveness to MAGE-A3
vaccination (Ulloa-Montoya et al., 2013; Wang et al., 2013a).
The signature was defined by comparing the global transcription
of pretreatment lesions from patients with metastatic melanoma
who experienced clinical benefit with those from patients who16 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.did not. A classifier consisting of 84 genes discriminated the
two groups and was also predictive of prolonged survival. This
classifier was highly enriched in immune-related genes, which
were coordinately overexpressed in lesions from responding
patients. Impressively, these genes largely overlap with those
observed in the ipilimumab trial (Ji et al., 2012). Transcripts
upregulated in responding lesions included genes coding for
specific chemokines (CXCL2, CXCL9, CXCL10, and CCL5),
cytotoxic granules (GZMK), HLA class I and II molecules,
T cell-surface markers (CD3D, CD8A, and IL2RG), T cell-activa-
tion markers (ICOS and CD86), NK cell-associated genes
(KLRD1 and KLRB1), and other classical IFN-stimulated genes
(STAT1, IRF1, JAK2, PSMB9, GBP1, GBP5, and FAM26F).
Network analysis of the genes included in the classifier revealed
that this signature bears the Th1 cell and IFN-g fingerprint.
Further, a 61-gene signature was validated by real-time qPCR,
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assessing the efficacy of postoperativeMAGE-A3 administration
in patients with stage I–IIB non-small cell lung cancer (NSCLC).
The presence of this similarity among different cancer pathol-
ogies supports a classification of cancer immune responsive-
ness independently of their tissue origin. Nevertheless, the
MAGE-A3 gene signature did not predict relapse or survival in
patients with NSCLC treated with placebo, suggesting that, in
this setting, it bears a strictly predictive role. The studywas, how-
ever, grossly underpowered in the detection of differences in
subgroup analyses stratified according to histotype or clinical
stage.
An increasing number of observations suggest that the pres-
ence of T cell immune infiltrates could favorably influence treat-
ment responsiveness to cytotoxic agents. In hepatic metastases
of CRC, high densities of CD3+, CD8+, and Granzyme B+ cells
at the IM were predictive of prolonged relapse-free survival in
patients treated with conventional chemotherapy +/ cetuximab
or bevacizumab antibody therapy (Halama et al., 2011). The
survival benefit of 5-fluorouracil-based chemotherapy in CRC
patients was greatly improved by the presence of tumor-infil-
trating lymphocytes (Morris et al., 2008). By analyzing samples
from patients enrolled in a large phase III trial, Loi et al. (2013)
showed that, in HER2-positive early-stage breast cancer, the
presence of lymphocyte infiltration predicts the response to
non-antracycline-based adjuvant chemotherapy. Moreover, the
presence of intratumoral lymphocytes, associated with the
upregulation of the T cell-related transcripts CD3D and CXCL9,
was a significant independent predictor of pathologic complete
response in patients with breast cancer treated with neoadjuvant
chemotherapy (Denkert et al., 2010). In the same settings, a
meta-analysis of eight microarray data sets (Ignatiadis et al.,
2012) showed that two (previously published) immune-signa-
tures genes (Desmedt et al., 2008; Teschendorff et al., 2007),
of which one centered on STAT1-IFN-stimulated genes, were
associated with complete remission after neoadjuvant chemo-
therapy (Ignatiadis et al., 2012). Interestingly, the strongest
association was found in HER2-positive tumors, wherein the
predictive value was superior to those of 15 other published non-
immunologic signatures (Ignatiadis et al., 2012). Whether this
phenomenon is due to the ability of an immunologically active
microenvironment to enhance the cytotoxic activity of chemo-
therapeutic agents is still unknown. Alternatively, the cancer
cell death induced by chemotherapy may act as an ‘‘immune
adjuvant’’ by increasing the release of tumor-associated anti-
gens (Lake and van der Most, 2006), with consequent induction
of a more potent acute immune-mediated response in those
tumors bearing a subacute inflammatory phenotype.
Mechanistic Immune Signatures Associated with
Effective Immune Rejection in Distinct Types of Cancer
Determining the mechanisms associated with treatment suc-
cess (or failure) at the time when tumor rejection is occurring is
critical because it highlights the ultimate biological objective
of interventions aimed at inducing immune-mediated tumor
regression. Few studies have addressed this issue, however.
This lack of information is largely due to the intrinsic difficulty
of studying the tumor microenvironment in vivo (Marincola,
2011).We define intratumoral mechanistic signatures as those that
describe the effects of a given treatment, through direct obser-
vation of the target tissue (in this case the tumor) that allows
discrimination of the effect of treatment based on the behavior
of the studied lesion. The most accurate method for identifying
mechanistic signatures is monitoring intratumoral processes by
prospectively following, through noninvasive biopsies (e.g.,
fine-needle aspirate [FNA]), the same lesion before and after
treatment. In addition to the problem of safe and precise access
to the visceral sites, the scarce amount of material available for
analysis makes the evaluation of architectural changes of the
immune contexture difficult to assess. To overcome these
limitations, investigators have proposed to study the effect of
therapeutic immune manipulation by tracking early treatment-
induced transcriptional changes in easily accessible tumor
lesions (e.g., cutaneous and subcutaneous lesions) (Panelli
et al., 2002, 2007; Wang et al., 2002). Using this approach,
mechanistic signatures were investigated in patients affected
by metastatic melanoma undergoing treatment with systemic
IL-2 (Panelli et al., 2002; Wang et al., 2002; Weiss et al., 2011)
and in patients with primary basal cell carcinoma treated with
topic administration of a TLR7 agonist (imiquimod) (Panelli
et al., 2007). In a first study, FNA of cutaneous and subcutaneous
melanoma lesions was collected before and 3 hr after the first
and the fourth doses of IL-2 (Panelli et al., 2002). Intrinsic charac-
teristics of tumor lesions had a major impact on determining
reactivity to IL-2 administration. In fact, posttreatment biopsies
segregated according to sample origin independently of the
time point. Surprisingly, no evidence of lymphocyte migration
at the tumor site was observed at this early time point, as demon-
strated by the lack of overexpression of genes codifying for
proteins constitutively expressed by immune cells (i.e., CD3,
CD4, CD8, CD10, TCR, CD20, CD11, CD14, CD16 FC-g, and
CD83). Although microarray analysis of tumor biopsies does
not allow discernment of the individual contribution of different
cell types, the transcriptional changes induced by IL-2 adminis-
tration could be best explained by activation of macrophage and
monocyte functions in the absence of T cell migration. These
transcripts codify for IFN-stimulated genes preferentially
induced by the IFN-g-STAT1-IRF1 pathway and include GBP1,
HLA class II molecules, and CXCR3 ligand genes (i.e., CXCL9
and CXCL10). Another subset of proinflammatory chemokine
genes, including the CCR2 ligands CCL2 and CCL7 and the
CCR5 ligandsCCL3 andCCL4, was also overexpressed in post-
treatment lesions. Such chemokines mediate chemotaxis of
monocytes, NK cells, and activated cytotoxic and Th1 cells
(Franciszkiewicz et al., 2012). Overall, this transcriptional pro-
gram seems indicative of macrophage activation, probably
shifted toward an M1 lineage, which is thought to exert a power-
ful antitumor inflammatory function through the induction of a
polarized Th1 cell inflammation (Mantovani et al., 2008). Other
genes specifically activated in posttreatment tumor metastases
included cytokine receptors (e.g., IL2RB and IFNGR1), adhesion
molecules associated with mononuclear cell migration (e.g.,
SELP and VCAM1), and genes associated with cytotoxic mech-
anisms in monocytes, NK cells, and activated T cells (e.g., GCA
and GNLY). In a subsequent placebo-controlled, randomized
trial, a similar approach was employed to assess the molecular
variations induced in basal cell-carcinoma lesions by the topicalImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 17
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paired punch biopsies pre- and posttreatment revealed that
the inflammation induced by imiquimod was sustained by the
activation of the same molecular pathways modulated by IL-2.
However, imiquimod administration led to a more pronounced
activation of the immune effector function genes (e.g., GNLY,
PRF, and genes encoding the different granzymes), accompa-
nied by the induction of proapoptotic caspase genes (CSPs).
The concomitant overexpression of markers of immune infiltra-
tion (CD4, CD8, and CD56) strongly suggested that these proap-
optotic events are engaged by the coordinated activation of
cytotoxic cells eventually recruited through the aforementioned
chemokine pathways. The higher activation of immune-effector
genes induced by imiquimod is in line with the relatively higher
clinical activity of this agent (approximately 80%–90% of com-
plete remission rate). Interestingly, the upregulation of specific
inflammatory pathways was maximal in the arm treated with a
highly effective dose-intense schedule, indirectly underlying a
relationship between the degree of the inflammation and the
achievement of a clinical response. Another study, directed at
patients with metastatic melanoma treated with IL-2 and various
vaccination schedules, corroborated this hypothesis (Wang
et al., 2002). When the analysis of treatment-induced transcrip-
tional changes was stratified according to clinical response, it
was evident that the nonresponsive tumors displayed an
indolent and unreactive immune microenvironment. Conversely,
sensitive tumors, which subsequently underwent complete
remission, promptly reacted to immune stimulation by shifting
toward an acute inflammatory status through the activation of
the key transcription factor, IRF1. Weiss et al. (2011) profiled
FNA samples from a small but homogenous cohort of patients
with melanoma pre- and posttreatment with IL-2. The results
confirmed that IL-2 induces activation of molecular pathways
associated with monocyte activation, including the CCR5
signaling pathway. Comparison among posttreatment lesions
showed that the majority of pathways upregulated in responding
lesions were associated with effector immune responses. These
signatures included a broad upregulation of HLA class II
molecules, which are regulated by IFN-g-IRF-1 signaling. As
mentioned above, such transcriptional differences were already
observed when the same analysis was carried out in pretreat-
ment lesions, providing evidence that they represent a magnifi-
cation of a pre-existing phenomenon. Similar conclusions were
reached by Ji et al. (2012), who profiled prospectively excised
melanoma metastases before and 3 weeks after the first ipilimu-
mab administration. IFNG, CD8B, major histocompatibility
complex class II genes, CCL4, CCL5, CXCL9, CXCL11, NKG7,
GZMs, and PRF1 were all upregulated in post- compared to
pretreatment samples, and this enhancement was greater in
patients who subsequently experienced clinical benefit. Tran-
scriptional analysis of several melanoma metastases obtained
from two patients experiencing a mixed response to treatment
corroborated these findings (Carretero et al., 2012) The analysis
of divergent behavior of tumor lesions belonging to the same pa-
tient and treated simultaneously excludes from the tumor-host
algorithm modulatory variables related to the hosts’ genetic
background and/or to environmental factors. Comparisons
between multiple regressing and progressing melanoma
metastases obtained from two patients treated with either18 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.autologous vaccination (M-VAX) or IFN-a revealed that genes
differentially expressed by regressing versus progressing lesions
were associated with acute immune response. Induction of the
IRF-1-STAT-1 pathway was observed only in regressing lesions
and associated with the activation of chemokines (CCL3 and
CCL4) and genes associated with T and NK cell infiltration and
cytotoxic functions. Given that these lesions were excised
weeks or months after treatment administration, these data
(combined with the above-described observations) suggest
that the migration of immune cells at the tumor site is a relatively
late, yet necessary, event. The similarity between mechanistic
signatures associated with tumor rejection among distinct
immunotherapeutic approaches provides evidence that tissue
destruction triggered by different immune-therapy approaches
converges, when effective, into a single molecular mechanism.
Analogies between Mechanistic Immune Signatures
Associated with Cancer Rejection and Other Types of
Immune Rejection
In 1969, Jonas Salk proposed that chronic infections, allograft
rejections, autoimmune disorders, and cancers belong to a com-
mon phenomenon that he named the ‘‘delayed allergy reaction’’
(Salk, 1969). The existence of a paradoxical continuum among
different yet intriguingly similar immune-mediated conditions
described in the previous paragraphs seems pertinent to Salk’s
hypothesis. In the last decade, several observational studies
have molecularly characterized the mechanism underlying the
phenomenon of immune-mediated tissue-specific destruction
and its convergence into the activation of a limited number of
pathways included in the ICR (Wang et al., 2008).
Although it is clear that the primum movens leading to tissue
destruction differ among immune-meditated diseases, the over-
whelming analogies among molecular mechanisms activated in
tissue experiencing rejection suggest that the immune-mediated
tissue-destruction processes eventually converge into a com-
mon final pathway. This includes the coordinated activation of
IFN-stimulated genes toward a Th1 cell polarization, the recruit-
ment of cytotoxic cells through the production of specific che-
mokine ligands, and the activation of immune-effector function
genes. We defined these common themes as follows: (1) the
IFN-g-STAT1-IRF1-IFN-stimulated gene pathway; (2) the spe-
cific chemokine ligand pathway (CXCR3 and CCR5 ligand
pathway); and (3) the immune-effector function pathway (for
example, GZMs, PFR, GNLY, and CSPs). The themes pertain
not only to tumor rejection but also to most facets of immune-
mediated tissue-specific destruction.
Seventy years ago, Peter Medawar demonstrated that allo-
graft rejection is an immune-mediated phenomenon. In the mid
1950s, this phenomenon was shown to be similar to the process
that confers immunity to tuberculosis, also called cell-mediated
delayed hypersensitivity (Medawar, 1944). At the time, Peter
Gorer also advocated the role of humoral immunity in the devel-
opment of acute allograft rejection (Gorer, 1942). It is now clear
that both humoral and cellular immunity are involved in the path-
ogenesis of allograft rejection and that the international patho-
logic classification divides allograft rejection into T cell-mediated
and antibody-mediated rejection. However, by profiling a large
cohort of kidney biopsies with histopathological diagnosis of
acute allograft rejection, Mueller et al. (2007) showed that a
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gene-expression profile, correlated quantitatively with lesion
phenotypes defined according to standard histopathological
criteria. Although biopsies with the diagnosis of acute allograft
rejection had elevated scores, they displayed a similar gene-
expression pattern, irrespectively of the cellular or antibody-
mediated nature of rejection. This signature demonstrates
cytotoxic T cell infiltration, upregulation of IFN-g transcripts,
and activation of immune-effector genes such PRF1 and
GZMs. In a meta-analysis of four independent kidney-transplant
microarray databases, Saint-Mezard et al. (2009) found that the
most consistently upregulated genes in acute allograft rejection
were associated with antigen-presenting cells, CCR5 and
CXCR3 ligand pathways, IFN response, and immune-effector
functions. Recently, a comparative meta-analysis of 15 microar-
ray studies in kidney, heart, lung, and liver recipients confirmed
that these pathways are consistently activated during acute
allograft rejection. IRF1 and STAT1 were predicted to be the
key regulators of themajority of the upregulated genes extracted
from microarray data sets (Spivey et al., 2011). Similarly, in
GVHD, the infiltration of CD45RO+ effector memory T cells, ex-
pressing CXCR3 and markers of cytotoxicity, were associated
with the induction of IFN-stimulated genes and apoptotic mech-
anisms and correlated with the presence and severity of the
disease (Imanguli et al., 2009).
In several autoimmune diseases, including lupus erythema-
tous, rheumatoid arthritis, multiple sclerosis, Crohn’s disease,
autoimmune thyroiditis, and hepatitis, the importance of the
recruitment of activated T cells through the activation of the
CXCR3 and/or CCR5 pathway has been well established
(Ajuebor et al., 2006; Godessart and Kunkel, 2001; Rotondi
and Chiovato, 2011). It is also observed in other inflammatory
conditions such as chronic bronchitis (Costa et al., 2008), cardio-
vascular disease (Okamoto et al., 2008), and placental villitis
(Kim et al., 2009). By performing global gene-expression analysis
of synovial-lining regions by microarray, Yoshida et al. (2012)
showed that the expression levels of STAT1, IRF1, and specific
chemokines (CXCL9, CXCL10, and CCL5) were dramatically
increased in patients with rheumatoid arthritis compared with
controls (patients with osteoarthritis). In the liver of patients
chronically infected with hepatisis C virus, the overexpression
of CXCR3 ligands correlates with the grade of necroinflammation
and fibrosis (Zeremski et al., 2008). However, after IFN-a admin-
istration, the intrahepatic activation of IFN-stimulated genes
(Feld et al., 2007) associated with the induction of STAT1 phos-
phorylation (Sarasin-Filipowicz et al., 2008) and a sharp increase
in the serum level of CXCL9 and CXCL10 (Florholmen et al.,
2011) correlates with a sustained virologic response, resembling
patterns observed in cancer immunotherapy. These data illus-
trate the analogies between mechanistic signatures across im-
mune-mediated tissue destruction, including tumor rejection.
The Molecular Continuum between Prognostic,
Predictive, and Mechanistic Immune Signatures
As discussed in the previous paragraphs, prognostic, predictive,
andmechanistic immune signatures are largely overlapping, and
yet they are seen to be associated with remarkably different
phenomena. In the case of prognostic and predictive signatures,
their presence is not necessarily associated with evidence oftumor regression. Rather, they may underlie a subtle process,
wherein the rate of tumor growth is slowed (prognostic signa-
tures) or perhaps not affected at all (predictive signatures) unless
an intervention is applied to amplify their power through immune
manipulation of the host. On the contrary, mechanistic signa-
tures are observed during the active phase of tumor destruction,
and parallel signatures are observed in other immune events
wherein tissue-specific destruction occurs, such as allograft
rejection (Spivey et al., 2011; Wang et al., 2008). Themost logical
explanation for this paradoxical observation is that although
qualitatively redundant, these signatures may differ quantita-
tively in the number of transcripts affected and the intensity of
their activation. This explanation currently remains a conjecture,
because very little has been done to compare the intensity of the
responses within the context of the same disease and treatment.
Most studies performed thus far compare tissues transversally
across patients rather than longitudinally. Only a few studies
have reported comparisons between predictive andmechanistic
signatures by assessing pretreatment and post/during-treat-
ment events. A comparison of pre- versus posttreatment FNA
melanoma lesions demonstrated qualitatively similar but quanti-
tatively enhanced transcriptional patterns in patients who under-
went treatment with IL-2 and experienced tumor regression
(Weiss et al., 2011). Similar observations were made by Ji et al.
(2012) in the ipilimumab trials. Thus, the presence of immune
cells and their functional orientation may reflect a distinct
underlying biology of tumors that may affect their natural history
(prognostic signatures) or their likelihood of responding to
immune-stimulatory therapies (predictive signatures), or may
directly induce tumor rejection following a continuum crescendo
of intensity (mechanistic signatures) (Ascierto et al., 2011)
(Figure 3B). It could be hypothesized that the lowest level of
activation characterizes predictive signatures that cannot affect
tumor growth in natural conditions, followed by prognostic sig-
natures of insufficient intensity to cause complete eradication
but capable of controlling tumor growth. It is also possible that
in certain conditions, depending on the stage or (possibly) on
the cancer histotype (e.g., NSCLC, Ulloa-Montoya et al., 2013),
the relatively low degree of immune activation may be com-
pletely inadequate to slow down the progression or to coun-
teract the spread of cancer as it becomes insensitive to immune
surveillance during the process of immunoescape (Wang et al.,
2013a). This hypothesis might conciliate the apparently clashing
observations that the predictive MAGE-A3 immune signature
did not bear prognostic significance in stage I–IIB NSCLC
(Ulloa-Montoya et al., 2013), whereas the expression of CCL5
was associated with favorable prognosis in stage I NSCLC
adenocarcinoma (Moran et al., 2002).
Interestingly, it was reported that the majority of patients with
a strong, coordinated cytotoxic intratumoral T cell infiltration
(high Immunoscore) presented at the time of diagnosis with
early-stage CRC, whereas patients with a low cytotoxic
response evolved to late-stage disease (Mlecnik et al., 2011b).
This may argue for a local control of primary tumor growth by
cytotoxic T cells. Furthermore, the T stage and N stage were
no longer significant in Cox multivariate analysis together with
the Immunoscore, supporting the significant statistical depen-
dency of tumor progression and invasion with the intratumor
immune cell densities and the dominant importance of immuneImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 19
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Figure 4. Possible Mechanisms Contributing to the Overlapping
Signatures of the Immune Contexture and the ICR
A schematic describing the potential cancer-centric and host-centric
contributing factors, leading to the immune contexture and ICR. These are
counter balanced by immune escape mechanisms. PAMPS, pathogen-asso-
ciated molecular pattern.
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et al., 2011b) (Figure 3B). It should be emphasized that the incre-
mental scale of activation conjectured to explain the progression
from predictive to mechanistic signatures is only conceptual and
should probably be adjusted to the sensitivity of tumor cells to
immune destruction. In other words, the balance between the
strength of the immune response and the mechanisms adopted
by tumors to escape immune recognition, rather than the abso-
lute level of activation, is more likely to determine the overall re-
sults.
Intratumoral immune biomarkers measure the status of activa-
tion of a naturally protective mechanism, which, if successfully
elicited, will lead to tumor destruction. Thus, with a few excep-
tions, it is probable that predictive immune biomarkers will over-
lap with the prognostic and the mechanistic ones. This is not the
case, however, for nonimmune-related markers, in which prog-
nostic, predictive, and mechanistic ones only minimally overlap
(Figure 3C). In fact, nonimmune biomarkers measure intrinsic
characteristics linked with tumor cell biology. However, conven-
tional therapy (chemotherapy, tumor-centered target therapy,
and radiotherapy) aims in general at repressing (directly or
indirectly) the process identified by such biomarkers, making
the overlap between the prognostic, predictive, and mechanistic
a rare event. Although the redundancy between prognostic,
predictive, and mechanistic immune signatures could seem
obvious, the basis of its molecular continuum, to the best of
our knowledge, has been never formalized before. We hope to
have provided here sufficient and convincing arguments to
support this emerging concept.
The Proposed Origins of Immune Signatures
It remains largely unclear why some tumors display an inflam-
matory-favorable status and others do not. The complex and
dynamic interaction between cancer cells, stromal cells, and
immune cells makes it difficult to dissect the distinct contribu-
tion of the different cell subtypes in determining the desirable
phenotype. Gene-expression profiling of the whole tumor
allows the determination of the final molecular vector. Accord-
ing to a perhaps overly simplistic interpretation, it is generally20 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.assumed that the immune signature detected by profiling tumor
biopsies is mainly the result of the presence and/or the activa-
tion of immune cells. However, several observations suggest
that this immune signature can also reflect features of cancer
cells. By selectively profiling serous-tumor epithelium isolated
by laser microdissection, Callahan et al. (2008) showed that
expression of HLA class II molecules, as well as the expression
of IRF1 by tumor cells, correlated with the presence of CD8+
T cells. Similarly, Zeimet et al. (2009) found that IRF1 expres-
sion in ovarian cancer correlates with the presence of CD3+
T cells. However, only ovarian cancer cells invariably stained
positively for IRF1, which was expressed by a small fraction
of lymphocytes and not expressed at all by stromal cells. These
studies suggest that tumor cell signals contribute to the im-
mune signature. Moreover, they cannot substantiate that the
activation of HLA or IRF1 drives the CD8+ response rather
than representing the consequence of the release of IFN-g or
other immune stimulants by cytotoxic T cells. Gene signatures
implying constitutive activation of innate mechanisms including
IFN-stimulated genes in cancer cells have been described
(Monsurro` et al., 2010). The overexpression of IRF1 (Zeimet
et al., 2009) or a constitutional, yet mild, activation of pSTAT-
1 (Lesinski et al., 2007) has been observed in a significant
proportion of resting human cell lines, suggesting that intrinsic
cancer biology can potentially contribute, at least in part, to the
genesis of the immune signature. Concordantly, constitutive
activation of the JAK1-STAT1 pathway in a relatively high per-
centage of melanoma cells expanded in unconditioned culture
medium (De Giorgi et al., 2012, Soc. for Immunotherapy of
Cancer, abstract). By analyzing sample biopsies from mela-
noma metastatic patients through gene- and protein-expres-
sion arrays, Harlin et al. (2009) observed that a subset of
six chemokines (CCL2, CCL3, CCL4, CCL5, CXCL9, and
CXCL10) strongly correlated with the presence of T lympho-
cytes. By using the supernatant of melanoma cell lines
(secreting all the aforementioned chemokines), the authors
proved their ability to recruit CD8+ effector T cells in vitro. How-
ever, it should be taken into account that several cell types,
including activated T cells, DCs, macrophages, endothelial
cells, epithelial cells, and stromal cells, can secrete these che-
mokines (Balkwill, 2012; Castiello et al., 2011; Franciszkiewicz
et al., 2012). Recently, Spivey et al. (2012) defined three
different molecular subtypes of melanoma metastases based
on the top genes concordantly expressed by them and their
derived cell lines and also showing transcriptional efficiency
according to copy-number variation analysis. One class of
melanoma metastases, enriched in Th1 genes (e.g., GBP1,
STAT1, and CXCL10), was also enriched in several genes
associated with melanoma-specific processes along the MAP
kinase pathways, in agreement with those observed in breast
cancer (Ignatiadis et al., 2012). However, there was a lack
of correlation in the expression of the aforementioned chemo-
kines and Th1 genes among melanoma cell lines and their
parental metastases, suggesting that the determination of this
inflammatory phenotype does not represent a linear transposi-
tion of the cancer genetics (Bedognetti et al., 2012, ASCO,
abstract). Rather, it reflects a complex, multifactorial, in vivo
phenomenon probably resulting from the interactions (and
interdependency) between the genetics of the host and of the
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factors) (Figure 4).
Future Perspective
As described above, gene-expression profiling and computer-
assisted immunohistochemistry have provided novel insights
into mechanisms regulating the antitumor response. Future
investigations involving integration of high-throughput ap-
proaches should better define the dependency on the genetic
makeup of the individuals bearing the disease, on the somatic
mutations within cancer cells, or on other influencing elements
(Ogino et al., 2011; Uccellini et al., 2012; Wang et al., 2012;
Zitvogel et al., 2012). Emerging factors related to the host,
including lifelong environmental exposure to aspects such as
the microbiome, may alter immune responsiveness and should
be considered (Grivennikov et al., 2012). Multiple aspects could
therefore act as a modifier, contributing to the natural or treat-
ment-induced history of cancer. Thus, it will be important to
perform simultaneous, integrated analysis to assess the dy-
namic behavior of human cancer, encompassing inborn ge-
netic traits, somatic genetic and epigenetic alterations, and
environmental contributions (Bindea et al., 2010; Wang et al.,
2013b).
Novel sophisticated technologies are constantly emerging.
Collaborative projects, such as The Cancer Genome Atlas
(TCGA), make use of integrated platforms including exon
sequencing, genome-wide DNA methylation profiling, copy-
number analysis, SNP profiling, and microRNA profiling. These
strategies are utilized to explore the genomic landscape of can-
cer through a multidimensional approach and to define the
genetic basis of its heterogeneity. TCGA data have recently
been published for leukemia (Cancer Genome Atlas Research
Network, 2013), glioblastoma (Cancer Genome Atlas Research
Network, 2008), colorectal (Cancer Genome Atlas Network,
2012b), breast (Cancer Genome Atlas Network, 2012c; Verhaak
et al., 2013), ovarian (Cancer Genome Atlas Research Network,
2011), endometrial (Kandoth et al., 2013), and squamous cell
lung (Cancer Genome Atlas Research Network, 2012a) cancers.
These approaches have already facilitated detection of novel
somatic mutations (e.g., the HLA-A gene in squamous lung
cancers) and have better defined molecular alterations yielding
different tumor phenotypes. The TCGA breast cancer study
confirmed that the classification, based on intrinsic gene-
expression phenotypes, highly correlates with distinct DNA
methylation, microRNA, copy-number aberration, and protein
patterns, suggesting that heterogeneity occurs within, rather
than across, these main phenotypes. Because TCGA data are
publicly accessible, exploring the TCGA databases focusing
on immune-regulation pathways could provide novel insights
into the relationship between oncogenic processes and the
immune system. In colorectal cancers, similar integromics anal-
ysis has shown that inflammatory pathways are deregulated in
nonhypermutated versus hypermutated samples, which were
enriched in tumors bearing high microsatellite instability. These
findings support the correlation between microsatellite insta-
bility, density of T cell infiltration, and favorable prognosis,
described by several authors (Guidoboni et al., 2001; Nosho
et al., 2010). For ovarian cancer, a subcluster of ‘‘immunoreac-
tive’’ tumors, characterized by overexpression of CXCR3,CXCL10, and CXCL11 (Cancer Genome Atlas Research
Network, 2011), was associated with 3q26.2 (MECOM) amplifi-
cation. More recently this ‘‘immunoreactive’’ classification was
associated with greater OS in TCGA and in two independent
databases (Verhaak et al., 2013). The availability of germline
DNA sequences could thus facilitate exploration into the rela-
tionship between the genetics of the host and the development
of a favorable immune phenotype. Li et al., for example, com-
bined genome-wide association studies (GWASs) and TCGA
approaches to ascertain the contributions of germline (GWAS)
versus somatic (TCGA) variants in the oncogenic gene-expres-
sion pattern in breast cancer (Kim et al., 2013; Li et al., 2013).
The complexity and multidimensionality of orthogonal data
sets make the development of novel multifactorial bioinformatics
approaches an urgent requirement.
Beyond correlative studies, more mechanistic insights, aimed
at explaining the sources of the molecular immunosignatures,
are warranted. Functional characterization at the cell-specific
level requires the use of deconvolution algorithms. Deconvolu-
tion algorithms (Shen-Orr et al., 2010) could increase sensitivity
in detecting differentially expressed genes if the proportion of
different cell populations is available (Shen-Orr et al., 2010) by
solving linear-regression problems in which the cell-type-
specific gene expression values represent the regression coeffi-
cients (Zhao and Simon, 2010). If the proportion of the cell-type
population is not available, deconvolution can still be performed
if the expression of gene signatures in pure cell types is well
characterized (Abbas et al., 2009). However, deconvolution
might be prone to bias when applied to extremely heteroge-
neous and dynamic systems wherein the gene-expression
profile of pure samples cannot be considered an accurate
parameter of normalization. This is the case for tumor biopsies,
wherein the gene-expression profiles in predefined cell subsets
can change dramatically, influenced by cytokines, chemokines,
and additional neighboring cells within the tumor micro-
environment. Other approaches, such as flow cytometry and
immunohistochemistry, are recommended for validating a
deep characterization of the cellular component of a tumor
biopsy. Little is known, for example, about the molecular fea-
tures of other components of the tumor microenvironment in
dynamic conditions. In particular, plasticity and the modulatory
role of stromal cells are becoming increasingly understood
(Finak et al., 2008), and it is probable that they also contribute
to the development of the inflammatory phenotype (Muthusw-
amy et al., 2012; Jin et al., 2012, Soc. for Immunotherapy of Can-
cer, abstract). Additionally, wide patient-to-patient variability is
observed among tumor cell profiles, given that specific tumor
cell signatures are largely modulable following different stimuli
(Murtas et al., 2013). Other approaches could consist of single-
cell profiling following cell sorting or lasermicrodissection. These
procedures also face limitations because they could modify cell
physiology and induce a change in the gene and/or protein
expression profile, but they are indeed promising. Generating
tumor cell lines and matching their genomic and proteomic
profile with the in vivo immune contexture of their parental
metastases could help evaluate immune-activation characteris-
tics of tumor cells. Many of these approaches have technical or
practical restraints; therefore, a combination of techniques is
likely to represent the best strategy. Regardless of the approach,Immunity 39, July 25, 2013 ª2013 Elsevier Inc. 21
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trials, remains paramount.
Given the central role played by the activation of ICR pathways
in inducing immune-mediated tissue destruction, we believe that
strategies aimed at targeting the tumor microenvironment
through enhancement could dramatically impact therapeutic
outcomes in the near future. Combination therapies represent
an intriguing and emerging approach (Ascierto and Marincola,
2011; Melero et al., 2013). As described in this review, immuno-
therapeutic approaches share similar mechanisms of actions
and, therefore, are likely to interact in a synergistic fashion.
Strikingly, in patients with metastatic melanoma, the addition
of IL-2 to ipilimumab strongly enhances its efficacy (Prieto
et al., 2012). Similar combinations could be explored by com-
bining other drugs targeting immune-checkpoints such as anti-
PD-1 and anti-PD-L1 (B7-H1) (Melero et al., 2013). Interestingly,
Muthuswamy et al. (2012) have recently reported that a combi-
nation of IFN-a with a TLR3 agonist can dramatically and uni-
formly enhance the production of CXCL10 and CCL5 in human
colon tumor explants. Such a chemokine-modulatory regimen
(with the addition of a COX1 inhibitor to suppress the regulatory
CCL22 chemokine) is currently being tested in phase I/II trials.
In addition, once somatic mutations and epigenetic characteris-
tics of tumor cells have been linked with immunosuppressive
characteristics, targeting the driver oncogene would represent
an indirect way to revert the immunosuppressive phenotype,
therefore facilitating the effectiveness of immunotherapy (Ribas
and Wolchok, 2013).
Pathological evaluation of the immune contexture using the
Immunoscore as part of the routine diagnostic and prognostic
assessment of tumors may provide crucial novel prognostic
information, facilitate clinical decision-making, including rational
stratification of patient treatment, and guide therapeutic
strategies (Bindea et al., 2010; Page`s et al., 2010). Our groups,
together with the Society for Immunotherapy of Cancer, initiated
an international task force to promote the use of the Immu-
noscore in routine clinical practice (Galon et al., 2012). It is
now recognized that the clinical outcome can vary significantly
among patients within the same cancer stage. The current
AJCC/UICC TNM classification provides limited prognostic
information and does not predict response to therapy. Accu-
mulating data from large cohorts of human cancers has demon-
strated the impact of immune classification, which has a
prognostic value that may add to the significance of the current
classification and that has been demonstrated to be superior to
the AJCC/UICC TNM classification in CRC. It is therefore
imperative to begin to incorporate a standard test such as the
Immunoscore into the current classification, thus providing an
essential prognostic and potentially predictive tool. Given the
power of intratumor immune quantification, the Immunoscore
is likely to be important for the field of cancer beyond the field
of tumor immunology. Thus, the results of this international
Immunoscore task force may result in the implementation of
the Immunoscore as a new component for the classification of
cancer, designated TNM-I (TNM-Immune) (Galon et al., 2012).
A similar initiative could be applied for the validation of immune
gene signatures. The use of immune signatures could be
particularly useful in the case of metastatic patients when the
evaluation of the Immunoscore is unfeasible due to limited22 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.starting material (collected in general through FNA or punch
biopsies). As for immunotherapy, the MAGA-A3 gene signature
(Ulloa-Montoya et al., 2013), which largely overlaps with the
ipilimumab gene signature (Ji et al., 2012), encapsulating the
ICR pathways, is in an advanced phase of validation in two
MAGE-A3 phase III trials directed at patients with lung cancer
and metastatic melanoma.
We believe that the evaluation of these immune gene signa-
tures should be prospectively evaluated in early immunotherapy
trials assessing novel agents or agent combinations. So far, no
biomarkers allowing patient selection are available in the field.
Given that immunotherapy trials also compete with biological
target therapies, the availability of a validated gene signature
allowing the identification of patients more likely to respond to
immune manipulation would dramatically improve patient strati-
fication in early clinical-trial development.
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